Table 3.
Correlation between tumour BRCA1/2 defects and clinico-pathological factors
| Parameter | Non mut/meth (n=81) | BRCA1 meth (n=10) | BRCA1/2 mut (n=18) | P-value |
|
|---|---|---|---|---|---|
| BRCA1 meth vs. non mut/meth | BRCA1/2 mut vs. non mut/meth | ||||
| Age | |||||
| <59 | 33 (40.7) | 6 (60) | 12 (66.7) | 0.320 | 0.070 |
| ≥59 | 48 (58.6) | 4 (40) | 6 (33.3) | ||
| FIGO stage | 0.005 | 0.030 | |||
| I–II | 37 (45.7) | 0 (0) | 3 (16.7) | ||
| III–IV | 44 (54.3) | 10 (100) | 15 (83.3) | ||
| Pathology | 0.004 | <0.001 | |||
| High grade serous | 42 (51.9) | 10 (100) | 18 (100) | ||
| Non-high grade serous | 39 (47.6) | 0 (0) | 0 (0) | ||
| Cytoreduction | 1.000 | 0.440 | |||
| Macro <1 cm | 47 (58) | 7 (70) | 12 (66.7) | ||
| Macro ≥1 cm | 11 (13.6) | 2 (20) | 1 (5.5) | ||
| Missing | 23 (28.4) | 1 (10) | 5 (27.8) | ||
| Platinum sensitivity | 0.150 | 0.750 | |||
| PFI <6 mon | 17 (21) | 5 (50) | 3 (16.7) | ||
| PFI ≥6 mon | 48 (59.3) | 5 (50) | 13 (72.2) | ||
| No chemo/missing | 16 (19.8) | 0 (0) | 2 (11.1) | ||
FIGO, International Federation of Gynecology and Obstetrics; Non mut/meth, BRCA1/2 wild type non-BRCA1-methylated; BRCA1 meth, BRCA1-methylated; BRCA1/2 mut, BRCA1/2-mutated; Macro, macroscopic residual disease; PFI, platinum-free interval.